Navigation Links
New, noninvasive, stool-based colorectal cancer screening test
Date:3/19/2014

(New York, March 19, 2014) A new, non-invasive, stool-based screening test detected 92% of colorectal cancer (CRC), according to a multicenter trial published online today in the New England Journal of Medicine. The new test, which is not yet approved by the FDA, allows patients to collect a sample at home without the need for bowel preparation or diet restrictions.

Unlike other available stool-based CRC screening tests, which rely solely on detecting occult blood in the stool, this new test, called "Cologuard", developed and patented by Exact Sciences, detects both occult blood and abnormal DNA that is shed by polyps and cancers. Although a colonoscopy is the preferred CRC screening method in most of the United States, about 30-35% of individuals do not get screened. Until now, stool-based CRC screening tests that were based on detecting occult blood in the stool had many false-positives and false-negatives; not all blood in the stool is from a polyp or cancer, and not all cancers bleed enough to be detected.

"This test is done in the privacy of your home, on a single specimen, and shipped directly to the lab without the need for freezing the sample," says Steven Itzkowitz, MD, a trial investigator and Professor of Medicine and Director of the Gastroenterology Fellowship Program at the Icahn School of Medicine at Mount Sinai.

In the study, participants submitted a stool sample for a commercial occult blood fecal immunochemical test (FIT) as well as for the new multi-target stool DNA test. Everyone then had a colonoscopy as the gold-standard comparator. All enrollees were considered "average-risk", meaning they were asymptomatic men and women 50 years or older, the segment of the population recommended for colorectal cancer screening. Data published today includes that the test detected 92% of colorectal cancer in patients versus FIT's 74%. The test also detected 42% of advanced pre-cancerous lesions in patients as compared to 24% for FIT.

The test might also be useful as an 'interval' look between colonoscopies to make sure lesions are not developing before the next scheduled colonoscopy for higher-risk individuals who are advised to get more frequent colonoscopies.

Dr. Itzkowitz is on the Scientific Advisory Board of Exact Sciences Corporation.

This study was funded by Exact Sciences Corporation.

Other authors include experts from Indiana University, University of North Carolina, Mayo Clinic Rochester, MN; Kaiser Permanente Medical Center, Walnut Creek, California; Boston Biostatistics Research Foundation, Boston, MA; and Exact Sciences Corporation, Madison, WI.

The Cologuard test is limited to investigational use only and is not available for sale in the United States.


'/>"/>

Contact: Johanna Younghans
johanna.younghans@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
2. Study says screening accounts for much of black/white disparity in colorectal cancer
3. Blacks and Hispanics at higher risk for precancerous colorectal polyps
4. Geisel researchers sift through junk to find colorectal cancer clues
5. Blood pressure drugs dont protect against colorectal cancer
6. NIH study finds sigmoidoscopy reduces colorectal cancer rates
7. Colonoscopy screening markedly reduces colorectal cancer incidence and death
8. Surgical patient safety program lowers SSIs by one-third following colorectal operations
9. A recipe for increased colorectal cancer screening rates
10. Gene mutation identifies colorectal cancer patients who live longer with aspirin therapy
11. New electrically-conductive polymer nanoparticles can generate heat to kill colorectal cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine ... announce one of their physicians has been invited to be a featured speaker at ... Practice Review conference on April 30, 2016. , Dr. R. Scott McPherson, a ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... 29, 2016 , ... Jvion, the market leader in clinical ... Eastside Partners, with participation from existing investor Martin Ventures. The funds will ... technology and product roadmap. , “Jvion is experiencing significant growth and ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Nike Softball ... softball camp from July 24th – 27th for girls aged 10-18. All facets of ... held at the beautiful Clark V. Whited Complex, one of the finest softball facilities ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
(Date:4/28/2016)... , April 28, 2016 ... , George Phillips und ... Unternehmens    ArisGlobal®, ein führender ... Sciences, gab heute bekannt, dass neue Führungskräfte ... Unternehmens gestoßen sind, die vielfältige Erfahrungen mitbringen. ...
(Date:4/28/2016)... -- Treato , the single largest ... that it has been named a Cool Vendor by ... Sciences, 2016, Stephen Davies , Michael ... life-science- oriented analytics, algorithms and smart machine technology in ... medication ingestion, and analyze unstructured information.   ...
Breaking Medicine Technology: